Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jordan Dolin
AddedMar 31, 2024
UpdatedMay 31, 2026
Jordan Dolin

Jordan Dolin

Board Member, Resonance Medical

Crunchbase

Jordan Dolin's Career

Resonance Medical
Resonance Medical

Chicago, IL, US

Board Member· Board
4D Healthware
4D Healthware

Chicago, IL, US

Board Member· Board
CancerIQ
CancerIQ

Chicago, IL, US

Board Member· Board
Fibroblast
Fibroblast

Chicago, IL, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jordan Dolin's Career

Resonance Medical
Resonance Medical
Angel$1.3M32014Chicago, IL, US
Board Member· Board

Leadership at Resonance Medical

Chris HeddonChris HeddonCo-Founder
Patrick RichardsPatrick RichardsCo-Founder
Allison HeddonAllison HeddonCo-Founder
4D Healthware
4D Healthware
Pre-Seed$5.6M352012Chicago, IL, US
Board Member· Board

Leadership at 4D Healthware

Star CunninghamStar CunninghamFounder
James McClungJames McClungBoard Member
CancerIQ
CancerIQ
Series B$20M492013Chicago, IL, US
Board Member· Board

Leadership at CancerIQ

Feyi OlopadeFeyi OlopadeCo-Founder
Joel KrikstonJoel KrikstonBoard Member
Olufunmilayo OlopadeOlufunmilayo OlopadeCo-Founder
Haibo LuHaibo LuCo-Founder

Similar to CancerIQ

MyCancerDBMyCancerDBStockbridge, VT, USGenomic Analysisest. 2019MyCancerDBStockbridge, VT, US · est. 2019

MyCancerDB: A platform leveraging genomic data for personalized cancer treatment options.

Angel · $110k9
FreenomeFreenomeSouth San Francisco, CA, USCancer Detectionest. 2014FreenomeSouth San Francisco, CA, US · est. 2014

Freenome, a US-based company, is dedicated to providing tools for cancer detection, treatment, and prevention.

Late Stage Private · $1.1B375
PreciseDxPreciseDxNew York City, NY, USCancer Risk Analysisest. 2019PreciseDxNew York City, NY, US · est. 2019

PreciseDx: Personalized cancer risk analysis for improved patient treatment outcomes.

Series A · $10.8M19
Fibroblast
Fibroblast
Seed$2.9M302010Chicago, IL, US
Board Member· Board

Leadership at Fibroblast

Andrew Albert MD MPHAndrew Albert MD MPHCo-Founder
Scott VoldScott VoldCo-Founder

Similar to Fibroblast

DoctibleDoctibleSan Diego, CA, USPractice Managementest. 2013DoctibleSan Diego, CA, US · est. 2013

Doctible: A healthcare SaaS platform automating workflow and engaging patients for growth.

Seed · $4.9M58
NexHealthNexHealthSan Francisco, CA, USHealthcare Softwareest. 2017NexHealthSan Francisco, CA, US · est. 2017

NexHealth: Streamlining healthcare with EHR-integrated solutions for patients, doctors, and developers.

Series C · $177.2M313
FiboFiboSan Francisco, CA, USest. 2016FiboSan Francisco, CA, US · est. 2016

Smart SaaS solutions for businesses, streamlining workflows with web and mobile software.

Seed · $1.8M

Jordan Dolin's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Jordan Dolin

Michael YangMichael YangBoard Member · Kiwi CrateDouglas RothDouglas RothBoard Member · NIXXYPeter HenigPeter HenigBoard Member · Linkage BiosciencesDavid DouglassDavid DouglassBoard Member · Astute MedicalPeter GyenesPeter GyenesBoard Member · RealPageSteven EinsteinSteven EinsteinBoard Member · Womensvcfund II